Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366654 | 0.85 | AADAT (0.44) | AADATCYP26A1CYP24A1CYP19A1CMA1 | |
| SCHEMBL365625 | 0.84 | SIGMAR1 (0.41) | AADATSIGMAR1CYP26A1CYP24A1CMA1 | |
| SCHEMBL15182499 | 0.82 | AADAT (0.47) | AADATSIGMAR1CMA1 | |
| SCHEMBL6837143 | 0.78 | AADAT (0.45) | AADATSIGMAR1CMA1 | |
| SCHEMBL365853 | 0.78 | AADAT (0.45) | AADATCMA1 | |
| SCHEMBL6837301 | 0.75 | ALDH1A1 (0.48) | AADATCMA1 | |
| SCHEMBL365659 | 0.75 | ALDH1A1 (0.48) | AADATCMA1 | |
| SCHEMBL29191609 | 0.72 | AADAT (0.51) | AADATCMA1 | |
| SCHEMBL29191592 | 0.72 | AADAT (0.51) | AADATCMA1 | |
| SCHEMBL365849 | 0.72 | AADAT (0.44) | AADATCYP19A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK SHARP & DOHME CORP. | 2013-09-26 | — | — | US | disclosed |
| EP-2593277-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009000-A2 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252944-A1 | NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | AADAT 837/4885SIGMAR1 211/4885CYP26A1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.